Review

anti egfl6 antibody (Bioss)

Name: anti egfl6 antibody
Brand: Bioss
Rating: 94 (2 reviews)

Bioss is a verified supplier

Bioss manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bioss anti egfl6 antibody

<t>EGFL6</t> expression levels in UCEC. A Analysis of EGFL6 expression using the TCGA-UCEC dataset (Wilcoxon rank-sum test, p < 0.001). B EGFL6 expression in paired UCEC samples (t-test, n = 23). C ROC curve of EGFL6 in UCEC. D EGFL6 expression in adjacent noncancerous tissues (scale bar: 100 μm). E EGFL6 expression in UCEC tissues (scale bar: 100 μm). F Statistical analysis of IHC results (t-test, n = 20). (* P < 0.05, ** P < 0.01, *** P < 0.001).

Anti Egfl6 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti egfl6 antibody/product/Bioss
Average 94 stars, based on 2 article reviews

anti egfl6 antibody - by Bioz Stars, 2026-02

94/100 stars

Images

1) Product Images from "Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration"

Article Title: Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration

Journal: Scientific Reports

doi: 10.1038/s41598-025-07379-7

EGFL6 expression levels in UCEC. A Analysis of EGFL6 expression using the TCGA-UCEC dataset (Wilcoxon rank-sum test, p < 0.001). B EGFL6 expression in paired UCEC samples (t-test, n = 23). C ROC curve of EGFL6 in UCEC. D EGFL6 expression in adjacent noncancerous tissues (scale bar: 100 μm). E EGFL6 expression in UCEC tissues (scale bar: 100 μm). F Statistical analysis of IHC results (t-test, n = 20). (* P < 0.05, ** P < 0.01, *** P < 0.001).

Figure Legend Snippet: EGFL6 expression levels in UCEC. A Analysis of EGFL6 expression using the TCGA-UCEC dataset (Wilcoxon rank-sum test, p < 0.001). B EGFL6 expression in paired UCEC samples (t-test, n = 23). C ROC curve of EGFL6 in UCEC. D EGFL6 expression in adjacent noncancerous tissues (scale bar: 100 μm). E EGFL6 expression in UCEC tissues (scale bar: 100 μm). F Statistical analysis of IHC results (t-test, n = 20). (* P < 0.05, ** P < 0.01, *** P < 0.001).

Techniques Used: Expressing

Analysis of DEGs associated with EGFL6 in UCEC. A Volcano plot illustrating EGFL6-related DEGs in UCEC. B Top 10 EGFL6-related DEGs in UCEC. C GO and KEGG analysis of the DEGs. D GSEA of DEGs in UCEC. (* P < 0.05, ** P < 0.01, *** P < 0.001).

Figure Legend Snippet: Analysis of DEGs associated with EGFL6 in UCEC. A Volcano plot illustrating EGFL6-related DEGs in UCEC. B Top 10 EGFL6-related DEGs in UCEC. C GO and KEGG analysis of the DEGs. D GSEA of DEGs in UCEC. (* P < 0.05, ** P < 0.01, *** P < 0.001).

Techniques Used:

Figure Legend Snippet: Methylation profile of EGFL6 in UCEC. A Heatmap depicting the methylation levels of EGFL6 in UCEC. Relations between specific methylation sites and patient outcomes are shown for: B cg07810164, C cg00932276, D cg12817924, E cg26310256, F cg23083672, and G cg12461113.

Techniques Used: Methylation

Relation between EGFL6 expression and immune cell infiltration. A Overall correlation between EGFL6 expression and various immune cell populations. B Correlation with Tregs. C Correlation with CD8 + T cells. D Correlation with resting dendritic cells. E Association with Tregs. F Association with CD8 + T cells. G Association with resting dendritic cells. (* P < 0.05, ** P < 0.01, *** P < 0.001).

Figure Legend Snippet: Relation between EGFL6 expression and immune cell infiltration. A Overall correlation between EGFL6 expression and various immune cell populations. B Correlation with Tregs. C Correlation with CD8 + T cells. D Correlation with resting dendritic cells. E Association with Tregs. F Association with CD8 + T cells. G Association with resting dendritic cells. (* P < 0.05, ** P < 0.01, *** P < 0.001).

Techniques Used: Expressing

EGFL6 expression is closely correlated with various clinical subgroups of UCEC. A Age. B Histologic grade: G2/G3. C BMI. D Therapy outcome: PR or CR. E Tumor invasion: ≤50%. F Receipt of radiation therapy. G Diabetes status. H Hormone therapy: No. I Menopause status: postmenopausal.

Figure Legend Snippet: EGFL6 expression is closely correlated with various clinical subgroups of UCEC. A Age. B Histologic grade: G2/G3. C BMI. D Therapy outcome: PR or CR. E Tumor invasion: ≤50%. F Receipt of radiation therapy. G Diabetes status. H Hormone therapy: No. I Menopause status: postmenopausal.

Techniques Used: Expressing

Image Search Results

Journal: Scientific Reports

Article Title: Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration

doi: 10.1038/s41598-025-07379-7

Figure Lengend Snippet: EGFL6 expression levels in UCEC. A Analysis of EGFL6 expression using the TCGA-UCEC dataset (Wilcoxon rank-sum test, p < 0.001). B EGFL6 expression in paired UCEC samples (t-test, n = 23). C ROC curve of EGFL6 in UCEC. D EGFL6 expression in adjacent noncancerous tissues (scale bar: 100 μm). E EGFL6 expression in UCEC tissues (scale bar: 100 μm). F Statistical analysis of IHC results (t-test, n = 20). (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The sections were incubated overnight at 4 °C with a primary anti-EGFL6 antibody (Bioss, cat. no. bs-13062R) diluted at 1:100.

Techniques: Expressing

Journal: Scientific Reports

Article Title: Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration

doi: 10.1038/s41598-025-07379-7

Figure Lengend Snippet: Analysis of DEGs associated with EGFL6 in UCEC. A Volcano plot illustrating EGFL6-related DEGs in UCEC. B Top 10 EGFL6-related DEGs in UCEC. C GO and KEGG analysis of the DEGs. D GSEA of DEGs in UCEC. (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The sections were incubated overnight at 4 °C with a primary anti-EGFL6 antibody (Bioss, cat. no. bs-13062R) diluted at 1:100.

Techniques:

Journal: Scientific Reports

Article Title: Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration

doi: 10.1038/s41598-025-07379-7

Figure Lengend Snippet: Methylation profile of EGFL6 in UCEC. A Heatmap depicting the methylation levels of EGFL6 in UCEC. Relations between specific methylation sites and patient outcomes are shown for: B cg07810164, C cg00932276, D cg12817924, E cg26310256, F cg23083672, and G cg12461113.

Article Snippet: The sections were incubated overnight at 4 °C with a primary anti-EGFL6 antibody (Bioss, cat. no. bs-13062R) diluted at 1:100.

Techniques: Methylation

Journal: Scientific Reports

Article Title: Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration

doi: 10.1038/s41598-025-07379-7

Figure Lengend Snippet: Relation between EGFL6 expression and immune cell infiltration. A Overall correlation between EGFL6 expression and various immune cell populations. B Correlation with Tregs. C Correlation with CD8 + T cells. D Correlation with resting dendritic cells. E Association with Tregs. F Association with CD8 + T cells. G Association with resting dendritic cells. (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The sections were incubated overnight at 4 °C with a primary anti-EGFL6 antibody (Bioss, cat. no. bs-13062R) diluted at 1:100.

Techniques: Expressing

Journal: Scientific Reports

Article Title: Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration

doi: 10.1038/s41598-025-07379-7

Figure Lengend Snippet: EGFL6 expression is closely correlated with various clinical subgroups of UCEC. A Age. B Histologic grade: G2/G3. C BMI. D Therapy outcome: PR or CR. E Tumor invasion: ≤50%. F Receipt of radiation therapy. G Diabetes status. H Hormone therapy: No. I Menopause status: postmenopausal.

Article Snippet: The sections were incubated overnight at 4 °C with a primary anti-EGFL6 antibody (Bioss, cat. no. bs-13062R) diluted at 1:100.

Techniques: Expressing

a, Human normal ovary, ovarian tumor, and healing wound tissues were dissociated, and isolated endothelial cells and samples were processed for microarray. b, Gene microarray of endothelial cells from normal ovary, healing-wound tissue, and ovarian tumor–associated endothelial cells. c, Expression of EGFL6 in human normal ovary, wound, and ovarian tumor samples. Representative images were taken from different samples. Scale bar =100 µm d, Validation of gene microarray data using q-PCR.(Normal ovary; n = 5, Ovarian tumor; n = 10, Wound; n = 7). Validation Error bars indicates SEM. *p<0.05 vs. Normal. See also Figure S1.

Journal: Cell reports

Article Title: Differential effects of EGFL6 on tumor versus wound angiogenesis

doi: 10.1016/j.celrep.2017.11.020

Figure Lengend Snippet: a, Human normal ovary, ovarian tumor, and healing wound tissues were dissociated, and isolated endothelial cells and samples were processed for microarray. b, Gene microarray of endothelial cells from normal ovary, healing-wound tissue, and ovarian tumor–associated endothelial cells. c, Expression of EGFL6 in human normal ovary, wound, and ovarian tumor samples. Representative images were taken from different samples. Scale bar =100 µm d, Validation of gene microarray data using q-PCR.(Normal ovary; n = 5, Ovarian tumor; n = 10, Wound; n = 7). Validation Error bars indicates SEM. *p<0.05 vs. Normal. See also Figure S1.

Article Snippet: Anti-EGFL6 monoclonal antibodies were identified by screening a large panel of single memory B cells collected from rabbits after immunization with recombinantly expressed human EGFL6 protein (SinoBiological, Beijing, China).

Techniques: Isolation, Microarray, Expressing

a, Graph of wound area on mice treated with either control IgG antibody or DC101 (anti-VEGFR2) quantified on days 0 through 15 after a skin excision wound. (n=10 mice per group); error bars indicate SEM. *p<0.05 vs. Control IgG. b, One day after SKOV3ip1 tumor cell injection, a wound was created on the dorsal side of the mice. Animals were treated with either Control siRNA-CH or mEGFL6 siRNA-CH. Graphical depiction of wound areas quantified on days 0 through 15 after skin excision wound. c, Effect of mEGFL6 silencing on tumor growth; representative images of tumor burden. Tumor weights are shown in d and numbers of tumor nodules in e. (n=10 mice per group); error bars indicate SEM. *p<0.05 vs. Control siRNA. f, Hind limb ischemia. After arterial ligation, mice were separated into 3 groups (n = 5 mice per group): normal, ischemia-24 h, and 96 h. Blood flow was monitored before and after femoral artery ligation with use of serial color doppler. At each time point, tissue was harvested and frozen so that immunofluorescence staining could be performed. g, EGFL6 expression was increased in endothelial cells in the ischemic (hypoxic) condition compared with the normal conditions. Error bars indicate SEM. *p<0.05 vs. Normal. See also Figure S2.

Journal: Cell reports

Article Title: Differential effects of EGFL6 on tumor versus wound angiogenesis

doi: 10.1016/j.celrep.2017.11.020

Figure Lengend Snippet: a, Graph of wound area on mice treated with either control IgG antibody or DC101 (anti-VEGFR2) quantified on days 0 through 15 after a skin excision wound. (n=10 mice per group); error bars indicate SEM. *p<0.05 vs. Control IgG. b, One day after SKOV3ip1 tumor cell injection, a wound was created on the dorsal side of the mice. Animals were treated with either Control siRNA-CH or mEGFL6 siRNA-CH. Graphical depiction of wound areas quantified on days 0 through 15 after skin excision wound. c, Effect of mEGFL6 silencing on tumor growth; representative images of tumor burden. Tumor weights are shown in d and numbers of tumor nodules in e. (n=10 mice per group); error bars indicate SEM. *p<0.05 vs. Control siRNA. f, Hind limb ischemia. After arterial ligation, mice were separated into 3 groups (n = 5 mice per group): normal, ischemia-24 h, and 96 h. Blood flow was monitored before and after femoral artery ligation with use of serial color doppler. At each time point, tissue was harvested and frozen so that immunofluorescence staining could be performed. g, EGFL6 expression was increased in endothelial cells in the ischemic (hypoxic) condition compared with the normal conditions. Error bars indicate SEM. *p<0.05 vs. Normal. See also Figure S2.

Techniques: Injection, Ligation, Immunofluorescence, Staining, Expressing

a, EGFL6 promoter reporter analysis under normoxia and hypoxic conditions. b, TWIST1 ectopic expression increases EGFL6 transcription activity. c, Increase in TWIST1 and EGFL6 expression in hypoxia and CoCl2 treatment. d, Ectopic expression of TWIST1 increases EGFL6 expression in RF24 cells. e, ChIP analysis of TWIST1 binding to EGFL6 promoter region in hypoxia compared with normoxia. Cross-linked chromatin from RF24 cells incubated in hypoxia chamber for 48 h and immunoprecipitated with TWIST1 or IgG control antibodies. The input and immunoprecipitated DNA was subjected to PCR using primers corresponding to the base pairs upstream of EGFL6 transcription start site. f, EGFL6 gene silencing using siRNA leads to increased cell death in hypoxia condition. (n = 3) **p<0.005, *p<0.05 See also Figure S3.

Journal: Cell reports

Article Title: Differential effects of EGFL6 on tumor versus wound angiogenesis

doi: 10.1016/j.celrep.2017.11.020

Figure Lengend Snippet: a, EGFL6 promoter reporter analysis under normoxia and hypoxic conditions. b, TWIST1 ectopic expression increases EGFL6 transcription activity. c, Increase in TWIST1 and EGFL6 expression in hypoxia and CoCl2 treatment. d, Ectopic expression of TWIST1 increases EGFL6 expression in RF24 cells. e, ChIP analysis of TWIST1 binding to EGFL6 promoter region in hypoxia compared with normoxia. Cross-linked chromatin from RF24 cells incubated in hypoxia chamber for 48 h and immunoprecipitated with TWIST1 or IgG control antibodies. The input and immunoprecipitated DNA was subjected to PCR using primers corresponding to the base pairs upstream of EGFL6 transcription start site. f, EGFL6 gene silencing using siRNA leads to increased cell death in hypoxia condition. (n = 3) **p<0.005, *p<0.05 See also Figure S3.

Techniques: Expressing, Activity Assay, Binding Assay, Incubation, Immunoprecipitation

$a, Expression level change in selected proteins after normalization by RPPA analysis. b and c, Western blotting of EGFL6-mediated activation of PI3K/AKT signaling, Tie2 and EGFR signaling. d, RF24 cells treated with Control (PBS) or EGFL6. Extracts were subjected to anti-Tie2 immunoprecipitation (IP) and integrin α5, αV, β1, and β3 detected by immunoblotting. e, Expression level of pTie2 and pAKT in cytosol and membrane fractions with Control (PBS) and EGFL6 treatment. αβ-tubulin was used as internal control of cytosolic fraction; NaK ATPase was used as membrane marker. f, Silencing of Integrin β1 (ITGB1) and Tie2 using specific siRNAs decreases Tie2 and AKT signaling. g–h, Silencing of Integrin β1 (ITGB1) and Tie2 decreases EGFL6-mediated tube formation (g) and migration (h) in endothelial cells. *p<0.05 vs. Control siRNA. In i–k, RGD blocking peptide decreases Tie2/AKT activation (i), tube formation (j) and migration (k). (n=3) *p<0.05 vs. Control. See also Figure S4.$

Journal: Cell reports

Article Title: Differential effects of EGFL6 on tumor versus wound angiogenesis

doi: 10.1016/j.celrep.2017.11.020

Figure Lengend Snippet: a, Expression level change in selected proteins after normalization by RPPA analysis. b and c, Western blotting of EGFL6-mediated activation of PI3K/AKT signaling, Tie2 and EGFR signaling. d, RF24 cells treated with Control (PBS) or EGFL6. Extracts were subjected to anti-Tie2 immunoprecipitation (IP) and integrin α5, αV, β1, and β3 detected by immunoblotting. e, Expression level of pTie2 and pAKT in cytosol and membrane fractions with Control (PBS) and EGFL6 treatment. αβ-tubulin was used as internal control of cytosolic fraction; NaK ATPase was used as membrane marker. f, Silencing of Integrin β1 (ITGB1) and Tie2 using specific siRNAs decreases Tie2 and AKT signaling. g–h, Silencing of Integrin β1 (ITGB1) and Tie2 decreases EGFL6-mediated tube formation (g) and migration (h) in endothelial cells. *p<0.05 vs. Control siRNA. In i–k, RGD blocking peptide decreases Tie2/AKT activation (i), tube formation (j) and migration (k). (n=3) *p<0.05 vs. Control. See also Figure S4.

Techniques: Expressing, Western Blot, Activation Assay, Immunoprecipitation, Marker, Migration, Blocking Assay

a, The binding affinity of recombinant EGFL6 to monoclonal antibody #93 and #135 was measured by Biacore. The dissociation constant (Kd) value of the monoclonal antibodies were calculated to be 1.89 nM (#93) and 2.19 nM (#135). b, Effect of EGFL6 blocking antibodies on Tie2/AKT activation in RF24 cells (n=3). c, Effect of EGFL6 blocking antibodies on wound healing in vivo (n=5 mice/group, #135; 5 mg/kg). d and e, EGFL6 antibodies decreased tube formation and migration of RF24 cells. f, Effect of EGFL6 blocking antibodies on tumor weight and tumor nodules in SKOV3ip1 tumor-bearing mice. Seven days after tumor cell injection, mice were randomly divided into three groups (10 mice/group) to receive therapy: (1) Control IgG Ab, (2) EGFL6 #93, and (3) EGFL6 Ab #135 (5 mg/kg). Antibody treatment was given once a week. g, Effect of targeted EGFL6 on proliferation (Ki67) and microvessel density (CD31). Scale bar = 100µm. The bars in the graphs correspond sequentially to the labeled columns of images on the left. Error bars indicates SEM. *p<0.05 vs. Control IgG. See also Figure S5.

Journal: Cell reports

Article Title: Differential effects of EGFL6 on tumor versus wound angiogenesis

doi: 10.1016/j.celrep.2017.11.020

Figure Lengend Snippet: a, The binding affinity of recombinant EGFL6 to monoclonal antibody #93 and #135 was measured by Biacore. The dissociation constant (Kd) value of the monoclonal antibodies were calculated to be 1.89 nM (#93) and 2.19 nM (#135). b, Effect of EGFL6 blocking antibodies on Tie2/AKT activation in RF24 cells (n=3). c, Effect of EGFL6 blocking antibodies on wound healing in vivo (n=5 mice/group, #135; 5 mg/kg). d and e, EGFL6 antibodies decreased tube formation and migration of RF24 cells. f, Effect of EGFL6 blocking antibodies on tumor weight and tumor nodules in SKOV3ip1 tumor-bearing mice. Seven days after tumor cell injection, mice were randomly divided into three groups (10 mice/group) to receive therapy: (1) Control IgG Ab, (2) EGFL6 #93, and (3) EGFL6 Ab #135 (5 mg/kg). Antibody treatment was given once a week. g, Effect of targeted EGFL6 on proliferation (Ki67) and microvessel density (CD31). Scale bar = 100µm. The bars in the graphs correspond sequentially to the labeled columns of images on the left. Error bars indicates SEM. *p<0.05 vs. Control IgG. See also Figure S5.

Techniques: Binding Assay, Recombinant, Blocking Assay, Activation Assay, In Vivo, Migration, Injection, Labeling

a, Tumor growth in Tie2;EGFL6 KO mice (KO) and WT mice. ID8 murine ovarian cancer cells were injected into KO and WT mice (n=10 mice per group). b, Double immunofluorescence staining of CD31 and EGFL6 in ID8 tumor from WT and KO mice. Scale bar = 100 µm. c, Bar graph represents tumor weight. d and e, Proliferation (Ki67) and microvessel density (CD31) counted in WT and KO mice tumor sections. Error bars indicate SEM. Scale bar = 100 µm. *p<0.05 vs. WT mice. f, Representative images of human ovarian cancer vasculature with low or high immunohistochemical staining for EGFL6. Scale bar =200 µm. Representative images were taken from different samples. g, Kaplan-Meier curves of disease-specific mortality of patients whose ovarian vasculature expressed low versus high EGFL6. See also Figure S6 and Table S1.

Journal: Cell reports

Article Title: Differential effects of EGFL6 on tumor versus wound angiogenesis

doi: 10.1016/j.celrep.2017.11.020

Figure Lengend Snippet: a, Tumor growth in Tie2;EGFL6 KO mice (KO) and WT mice. ID8 murine ovarian cancer cells were injected into KO and WT mice (n=10 mice per group). b, Double immunofluorescence staining of CD31 and EGFL6 in ID8 tumor from WT and KO mice. Scale bar = 100 µm. c, Bar graph represents tumor weight. d and e, Proliferation (Ki67) and microvessel density (CD31) counted in WT and KO mice tumor sections. Error bars indicate SEM. Scale bar = 100 µm. *p<0.05 vs. WT mice. f, Representative images of human ovarian cancer vasculature with low or high immunohistochemical staining for EGFL6. Scale bar =200 µm. Representative images were taken from different samples. g, Kaplan-Meier curves of disease-specific mortality of patients whose ovarian vasculature expressed low versus high EGFL6. See also Figure S6 and Table S1.

Techniques: Injection, Double Immunofluorescence Staining, Immunohistochemical staining, Staining

ScRNA-Seq analysis of keratocytes and the corneal endothelium. ( A ) Violin plots showing common and preferential expression of representative marker genes in keratocyte clusters. ( B ) Immunofluorescence staining of the whole cornea to demonstrate differential expression of genes, including Col14A1 and Egfl6, indicating different distributions within the stroma. ( C ) Violin plots showing common and preferential expression of representative marker genes in endothelial clusters. ( D ) Immunofluorescence staining of the whole cornea revealing the heterogenous expression of CD109 in endothelial cells.

Journal: Investigative Ophthalmology & Visual Science

Article Title: Single-Cell Transcriptomics Reveals Cellular Heterogeneity and Complex Cell–Cell Communication Networks in the Mouse Cornea

doi: 10.1167/iovs.64.13.5

Figure Lengend Snippet: ScRNA-Seq analysis of keratocytes and the corneal endothelium. ( A ) Violin plots showing common and preferential expression of representative marker genes in keratocyte clusters. ( B ) Immunofluorescence staining of the whole cornea to demonstrate differential expression of genes, including Col14A1 and Egfl6, indicating different distributions within the stroma. ( C ) Violin plots showing common and preferential expression of representative marker genes in endothelial clusters. ( D ) Immunofluorescence staining of the whole cornea revealing the heterogenous expression of CD109 in endothelial cells.

Article Snippet: EGFL6 , Bioss , bs-13062R , 1:50.

Techniques: Expressing, Marker, Immunofluorescence, Staining

The Detailed List of the Corresponding Antibodies and Desired Concentrations

Journal: Investigative Ophthalmology & Visual Science

Article Title: Single-Cell Transcriptomics Reveals Cellular Heterogeneity and Complex Cell–Cell Communication Networks in the Mouse Cornea

doi: 10.1167/iovs.64.13.5

Figure Lengend Snippet: The Detailed List of the Corresponding Antibodies and Desired Concentrations

Article Snippet: EGFL6 , Bioss , bs-13062R , 1:50.

Techniques:

Roles of CAFs-related risk score in the Xiangya real-world cohort (A) KM survival analysis of high- and low-CRRS group (n = 56, Log rank test, p = 0.0087). (B) Histogram showing the correlation between survival status and CAFs-related risk score. (C) Forest plot showing the independent prognostic value of CAFs-related risk score in the BLCA Xiangya real-world cohort (hazard ratio with 95% confidence interval). (D) ROC curves showing the predictive accuracy of CAFs-related risk score for overall survival in Xiangya real-world cohort. (E) Double-staining of EMP1/Collagen, P4HB/Vimentin, and EGFL6/α-SMA (Scale bar = 100 μm). (F) Expression of CD8, PD-L1, and CTLA4 in high- and low-CRRS group were detected by immunofluorescence (n = 56, Student’s t test) (Scale bar = 100 μm, data were represented as mean ± SEM). See also <xref ref-type=

Table S1 . " width="100%" height="100%">

Journal: iScience

Article Title: A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer

doi: 10.1016/j.isci.2023.107722

Figure Lengend Snippet: Roles of CAFs-related risk score in the Xiangya real-world cohort (A) KM survival analysis of high- and low-CRRS group (n = 56, Log rank test, p = 0.0087). (B) Histogram showing the correlation between survival status and CAFs-related risk score. (C) Forest plot showing the independent prognostic value of CAFs-related risk score in the BLCA Xiangya real-world cohort (hazard ratio with 95% confidence interval). (D) ROC curves showing the predictive accuracy of CAFs-related risk score for overall survival in Xiangya real-world cohort. (E) Double-staining of EMP1/Collagen, P4HB/Vimentin, and EGFL6/α-SMA (Scale bar = 100 μm). (F) Expression of CD8, PD-L1, and CTLA4 in high- and low-CRRS group were detected by immunofluorescence (n = 56, Student’s t test) (Scale bar = 100 μm, data were represented as mean ± SEM). See also Table S1 .

Article Snippet: Rabbit polyclonal anti- EGFL6 , Abmart , Cat# PH1602.

Techniques: Double Staining, Expressing, Immunofluorescence

Journal: iScience

Article Title: A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer

doi: 10.1016/j.isci.2023.107722

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti- EGFL6 , Abmart , Cat# PH1602.

Techniques: Fluorescence, Biomarker Discovery, Software

Review

Structured Review

Images

1) Product Images from "Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration"

Similar Products

Image Search Results